de Jong Marcus C, Kors Wijnanda A, de Graaf Pim, Castelijns Jonas A, Moll Annette C, Kivelä Tero
Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands.
Department of Pediatric Oncology, VU University Medical Center, Amsterdam, Netherlands.
Am J Ophthalmol. 2015 Dec;160(6):1116-1126.e5. doi: 10.1016/j.ajo.2015.09.009. Epub 2015 Sep 12.
To estimate the incidence of trilateral retinoblastoma in patients with retinoblastoma.
Systematic review and meta-analysis.
We searched Medline and Embase for scientific literature published between January 1966 and July 2015 that assessed trilateral retinoblastoma incidence. We used a random-effects model for the statistical analyses.
We included 23 retinoblastoma cohorts from 26 studies. For patients with bilateral retinoblastoma the unadjusted chance of developing trilateral retinoblastoma across all cohorts was 5.3% (95% confidence interval [CI]: 3.3%-7.7%); the chance of pineal trilateral retinoblastoma was 4.2% (95% CI: 2.6%-6.2%) and the chance of nonpineal trilateral retinoblastoma was 0.8% (95% CI: 0.4%-1.3%). In patients with hereditary retinoblastoma (all bilateral cases, and the unilateral cases with a family history or germline RB1 mutation) we found a trilateral retinoblastoma incidence of 4.1% (95% CI: 1.9%-7.1%) and a pineal trilateral retinoblastoma incidence of 3.7% (95% CI: 1.8%-6.2%). To reduce the risk of overestimation bias we restricted analysis to retinoblastoma cohorts with a minimum size of 100 patients, resulting in adjusted incidences of 3.8% (95% CI: 2.4%-5.4%), 2.9% (95% CI: 1.9%-4.2%), and 0.7% (95% CI: 0.3%-1.2%) for any, pineal, and nonpineal trilateral retinoblastoma, respectively, among patients with bilateral retinoblastoma. Among hereditary retinoblastoma we found an adjusted trilateral retinoblastoma incidence of 3.5% (95% CI: 1.2%-6.7%) and a pineal trilateral retinoblastoma incidence of 3.2% (95% CI: 1.4%-5.6%).
The estimated incidence of trilateral retinoblastoma is lower than what is reported in previous literature, especially after exclusion of small cohorts that were subject to overestimation bias in this context.
评估视网膜母细胞瘤患者中三侧性视网膜母细胞瘤的发病率。
系统评价和荟萃分析。
我们检索了1966年1月至2015年7月期间发表的评估三侧性视网膜母细胞瘤发病率的Medline和Embase科学文献。我们使用随机效应模型进行统计分析。
我们纳入了来自26项研究的23个视网膜母细胞瘤队列。对于双侧视网膜母细胞瘤患者,所有队列中发生三侧性视网膜母细胞瘤的未调整概率为5.3%(95%置信区间[CI]:3.3%-7.7%);松果体三侧性视网膜母细胞瘤的概率为4.2%(95%CI:2.6%-6.2%),非松果体三侧性视网膜母细胞瘤的概率为0.8%(95%CI:0.4%-1.3%)。在遗传性视网膜母细胞瘤患者(所有双侧病例,以及有家族史或种系RB1突变的单侧病例)中,我们发现三侧性视网膜母细胞瘤的发病率为4.1%(95%CI:1.9%-7.1%),松果体三侧性视网膜母细胞瘤的发病率为3.7%(95%CI:1.8%-6.2%)。为降低高估偏倚风险,我们将分析限制在最小规模为100例患者的视网膜母细胞瘤队列中,结果在双侧视网膜母细胞瘤患者中,任何、松果体和非松果体三侧性视网膜母细胞瘤的调整发病率分别为3.8%(95%CI:2.4%-5.4%)、2.9%(95%CI:1.9%-4.2%)和0.7%(95%CI:0.3%-1.2%)。在遗传性视网膜母细胞瘤中,我们发现三侧性视网膜母细胞瘤的调整发病率为3.5%(95%CI:1.2%-6.7%),松果体三侧性视网膜母细胞瘤 的发病率为3.2%(95%CI:1.4%-5.6%)。
三侧性视网膜母细胞瘤的估计发病率低于先前文献报道的发病率,尤其是在排除了在此背景下存在高估偏倚的小队列之后。